Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ABLYNX (D) : ABLYNX ANNOUNCES WARRANT EXERCISE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2012 | 07:17pm CEST
ABLYNX ANNOUNCES WARRANT EXERCISE GHENT, Belgium, 23 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that an additional 5,000 common shares have been issued by the Company in exchange for €7,000 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 43,709,895 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact: Ablynx:

Dr Edwin Moses

Chairman and CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch Investor Relations Manager t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com

M:Communications:

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t: +44 207 920 2330

e: ablynx@mcomgroup.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward - looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the
Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
08/17 ABLYNX : 17/08/2017 ablynx will announce its 2017 half year results with webcast..
08/17 ABLYNX : Will announce its 2017 half year results with webcast on 24 august 2017
08/11 ABLYNX : Announces warrant exercise
07/26 ABLYNX : 26/07/2017 ablynx receives fast track designation from the fda for capl..
07/26 ABLYNX : Receives fast track designation from the fda for caplacizumab for the t..
07/24 ABLYNX : Announces warrant exercise
07/20 ABLYNX : 20/07/2017 ablynx and sanofi enter into a strategic collaboration to de..
07/20 ABLYNX : And sanofi enter into a strategic collaboration to develop nanobody pro..
07/17 ABLYNX : 17/07/2017 ablynx proposes appointment of mrs hilde windels as a new in..
07/17 ABLYNX : Proposes appointment of mrs hilde windels as a new independent director
More news
News from SeekingAlpha
07/29 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 29, 2017
07/12 ABLYNX : Not Ready Just Yet
06/27 Ablynx earns ?2.5M milestone from collaboration partner Merck
06/15 Therapy Focus - Lupus Hopes Build But Data Remain On The Distant Horizon
06/06 Ablynx (ABLYF) Presents At Jefferies 2017 Global Healthcare Conference - Slid..
Financials (€)
Sales 2017 50,4 M
EBIT 2017 -60,2 M
Net income 2017 -71,4 M
Finance 2017 8,62 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 14,0x
EV / Sales 2018 13,7x
Capitalization 715 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 16,3 €
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX8.04%842
INCYTE CORPORATION26.03%25 577
QUINTILES IMS HOLDINGS INC20.36%20 048
LONZA GROUP40.35%17 923
CELLTRION, INC.--.--%11 720
ALKERMES PLC-7.12%7 923